Fredericksen Interviewed Over Trump Lawyer’s Decision to Drop Lawsuits Against BuzzFeed, Fusion GPS
19 April 2018
Partner Scott Fredericksen was interviewed on the CBS Evening News about Trump lawyer Michael Cohen’s decision to drop lawsuits against Fusion GPS and BuzzFeed, the organizations responsible for creating and publishing the so-called Steele dossier, which details alleged connections between the Trump campaign and Russia.
Fredericksen said material uncovered in civil cases is routinely used by prosecutors to make criminal cases. “In white collar criminal defense, the strategic choice is always made to protect the client in the criminal case first and second, don’t expose this person to further potential charges in the civil lawsuit by forcing him to testify,” he said.
Fredericksen said material uncovered in civil cases is routinely used by prosecutors to make criminal cases. “In white collar criminal defense, the strategic choice is always made to protect the client in the criminal case first and second, don’t expose this person to further potential charges in the civil lawsuit by forcing him to testify,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”